New insider activity at Boston Scientific ( (BSX) ) has taken place on May 21, 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Boston Scientific is seeing a wave of insider confidence as three directors recently snapped up additional shares. Director David Habiger acquired 4,450 shares of Boston Scientific stock in a transaction valued at $251,065. Director Edward Ludwig followed suit with the purchase of 3,580 shares worth $202,914. Adding to the buying spree, Director Cheryl Pegus bought 1,770 shares for a total of $99,987. These insider purchases collectively underscore a notable show of faith in the company’s prospects from its board members.
Recent Updates on BSX stock
Boston Scientific shares were influenced by news that its observational chronic pain study, “A DirEct to PatieNt Study in Chronic Pain,” has been completed and recently updated, even though top-line results are not yet posted. Analysts focused on how this real-world evidence could affect payer perceptions of safety, durability, and long-term effectiveness for the company’s interventional pain devices.
Commentary emphasized that positive outcomes may strengthen Boston Scientific’s competitive position and support more favorable reimbursement versus neuromodulation peers, while weaker signals could benefit rivals. These shifting expectations about future market adoption and pricing power were central to recent adjustments in sentiment and valuation assumptions around BSX over the last 24 hours.
Spark’s Take on BSX Stock
According to Spark, TipRanks’ AI Analyst, BSX is a Neutral.
The score is anchored by strong underlying financial performance (rising revenue scale, improving margins and returns) and a moderate P/E. It is offset by weak price trends and negative momentum (trading below all key moving averages) plus a more cautious earnings-call outlook with lowered guidance and margin/product headwinds.
To see Spark’s full report on BSX stock, click here.
More about Boston Scientific
YTD Price Performance: -40.57%
Average Trading Volume: 16,535,179
Technical Sentiment Signal: Sell
Current Market Cap: $84.23B